secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193125-25-175477
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NCCN SCLC guidelines add LEMS testing and amifampridine (FIRDAPSE) treatment recommendation
--------------------------------------------------------------------------------

- NCCN guidelines for SCLC updated to recommend VGCC antibody testing for LEMS diagnosis.
- Amifampridine (FIRDAPSE) added as a supportive care treatment option for LEMS in SCLC.
- Approximately 50% of LEMS cases are cancer-associated, most commonly with SCLC.
- Catalyst internal analysis suggests 90% of LEMS in SCLC patients may be undiagnosed.
- Guideline inclusion could increase clinical awareness and drive adoption of VGCC testing and amifampridine use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525175477/0001193125-25-175477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525175477/d55613d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-175477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer